BACKGROUND: Abnormal glucose metabolism in HIV-infected patients has largely been attributed to the use of protease inhibitors. However, most studies of glucose metabolism in HIV-infected patients have focused on men or have lacked appropriate control groups. METHODS: We assessed the factors associated with previously diagnosed diabetes among 620 middle-aged women with or at risk for HIV infection. For a subset of 221 women without previously diagnosed diabetes, we performed an oral glucose tolerance test (OGTT) to measure glucose and insulin levels, and we assessed factors associated with abnormal glucose tolerance, insulin resistance, and insulin secretion. RESULTS: Thirteen percent of the women in the present study had previously diagnosed diabetes. Among women without previously diagnosed diabetes who underwent an OGTT, 6% had previously undiagnosed diabetes, and 12% had impaired glucose tolerance (IGT). According to multivariate analysis, factors that were associated with previously diagnosed diabetes included current methadone treatment, body mass index of > or =25, family history of diabetes, and physical inactivity. Factors that were independently associated with an abnormal result of an OGTT (i.e., a result consistent with IGT or diabetes) included age > or =50 years, family history of diabetes, physical inactivity, and a high number of pack-years of smoking. Factors independently associated with insulin resistance included waist circumference, Hispanic ethnicity, physical inactivity, and, among HIV-infected women, use of HAART that did not include protease inhibitors. Factors associated with lower levels of insulin secretion included current opiate use (i.e., methadone or heroin) and older age. CONCLUSIONS: Abnormal glucose metabolism is highly prevalent among middle-aged women with or at risk for HIV infection, particularly women who use opiates. Screening for diabetes in the HIV primary care setting should occur for women who have classic risk factors for diabetes, rather than solely for women who are taking PIs. Interventions that target modifiable risk factors, including obesity and physical inactivity, are also warranted.
BACKGROUND:Abnormal glucose metabolism in HIV-infectedpatients has largely been attributed to the use of protease inhibitors. However, most studies of glucose metabolism in HIV-infectedpatients have focused on men or have lacked appropriate control groups. METHODS: We assessed the factors associated with previously diagnosed diabetes among 620 middle-aged women with or at risk for HIV infection. For a subset of 221 women without previously diagnosed diabetes, we performed an oral glucose tolerance test (OGTT) to measure glucose and insulin levels, and we assessed factors associated with abnormal glucose tolerance, insulin resistance, and insulin secretion. RESULTS: Thirteen percent of the women in the present study had previously diagnosed diabetes. Among women without previously diagnosed diabetes who underwent an OGTT, 6% had previously undiagnosed diabetes, and 12% had impaired glucose tolerance (IGT). According to multivariate analysis, factors that were associated with previously diagnosed diabetes included current methadone treatment, body mass index of > or =25, family history of diabetes, and physical inactivity. Factors that were independently associated with an abnormal result of an OGTT (i.e., a result consistent with IGT or diabetes) included age > or =50 years, family history of diabetes, physical inactivity, and a high number of pack-years of smoking. Factors independently associated with insulin resistance included waist circumference, Hispanic ethnicity, physical inactivity, and, among HIV-infectedwomen, use of HAART that did not include protease inhibitors. Factors associated with lower levels of insulin secretion included current opiate use (i.e., methadone or heroin) and older age. CONCLUSIONS:Abnormal glucose metabolism is highly prevalent among middle-aged women with or at risk for HIV infection, particularly women who use opiates. Screening for diabetes in the HIV primary care setting should occur for women who have classic risk factors for diabetes, rather than solely for women who are taking PIs. Interventions that target modifiable risk factors, including obesity and physical inactivity, are also warranted.
Authors: A Ceriello; D Giugliano; N Passariello; A Quatraro; P Dello Russo; R Torella; F D'Onofrio Journal: Horm Metab Res Date: 1987-09 Impact factor: 2.936
Authors: M C Pouliot; J P Després; S Lemieux; S Moorjani; C Bouchard; A Tremblay; A Nadeau; P J Lupien Journal: Am J Cardiol Date: 1994-03-01 Impact factor: 2.778
Authors: Yamil Gerena; Richard L Skolasky; Joyce M Velez; Dianedis Toro-Nieves; Raul Mayo; Avindra Nath; Valerie Wojna Journal: PLoS One Date: 2012-05-22 Impact factor: 3.240
Authors: Allison Longenberger; Jeong Youn Lim; Todd T Brown; Alison Abraham; Frank J Palella; Rita B Effros; Trevor Orchard; Maria Mori Brooks; Lawrence A Kingsley Journal: Future Virol Date: 2011-04 Impact factor: 1.831
Authors: Rakhi Kohli; Robert S Klein; Ellie E Schoenbaum; Kathryn Anastos; Howard Minkoff; Henry S Sacks Journal: J Urban Health Date: 2006-01 Impact factor: 3.671
Authors: Allison Longenberger; Jeong Youn Lim; Trevor Orchard; Maria Mori Brooks; Jennifer Brach; Kristen Mertz; Lawrence A Kingsley Journal: Futur HIV Ther Date: 2008-11
Authors: Michael J Carper; W Todd Cade; Margaret Cam; Sheng Zhang; Anath Shalev; Kevin E Yarasheski; Sasanka Ramanadham Journal: Am J Physiol Endocrinol Metab Date: 2008-01-02 Impact factor: 4.310